LakeShore Biopharma Co., Ltd (OTCPK: LSBCF; OTCPK: LSBWF) announced on May 28, 2026, that it has called an extraordinary general meeting of shareholders (EGM) to vote on a proposed merger that would take the company private. The EGM is scheduled for June 19, 2026, at 1:00 p.m. Beijing time at the company’s headquarters in Beijing.
The merger, initially announced on November 4, 2025, and amended on April 29, 2026, involves Oceanpine Skyline Inc. (Parent) and its wholly owned subsidiary Oceanpine Merger Sub Inc. If approved, Merger Sub will merge with and into LakeShore Biopharma, with the company surviving as a wholly owned subsidiary of Parent. Consequently, LakeShore’s ordinary shares and warrants would cease to be quoted on the OTC Pink tier of the OTC Markets and would no longer be registered under Section 12 of the Securities Exchange Act of 1934.
The company’s board of directors, following the unanimous recommendation of a special committee of independent directors, has authorized the merger and recommends that shareholders vote in favor. Shareholders of record as of May 27, 2026, are entitled to vote at the EGM. Additional details about the merger and the EGM are available in the transaction statement on Schedule 13E-3 and the definitive proxy statement filed with the U.S. Securities and Exchange Commission (SEC), accessible via the SEC’s website at http://www.sec.gov.
LakeShore Biopharma, formerly known as YS Biopharma, is a global biopharmaceutical company focused on developing vaccines and therapeutic biologics for infectious diseases and cancer. The company’s proprietary PIKA immunomodulating technology platform underpins its pipeline, which includes candidates for rabies, hepatitis B, influenza, and other viral infections.
The move to go private comes amid a challenging environment for small-cap biotech firms, where public market volatility and the costs of regulatory compliance can strain resources. By delisting, LakeShore may gain operational flexibility and the ability to focus on long-term research without the quarterly earnings pressures faced by public companies. However, the decision requires shareholder approval, and the company has urged investors to carefully review the proxy materials.
LakeShore operates in China, Singapore, and the Philippines, and its management team combines local expertise with global biopharmaceutical experience. The company’s website provides further information at https://investors.lakeshorebio.com/.
The outcome of the EGM will determine whether LakeShore proceeds with the merger, which would mark a significant transition for the company and its shareholders. The SEC filings contain important information about the transaction, including potential risks and the interests of company directors and officers in the deal.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is LakeShore Biopharma Calls Shareholder Meeting to Vote on Going-Private Merger.